Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perfectionism and choice deferral in online shopping: a moderated mediation model of fear of missing out and upward social comparison.

Frontiers in psychology·2026
Same author

"Digital eye tracking and plasma biomarkers: Distinguishing functional cognitive impairment from Alzheimer's disease biology".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Creative leadership and kindergarten teachers' creative teaching performance: A moderated mediation model.

Acta psychologica·2026
Same author

Diagnostic and Prognostic Utility of Plasma p-tau217 for Alzheimer's Disease in Chinese Elderly: Insights From the SILCODE Study With a Derived Threshold.

European journal of neurology·2026
Same author

Lamellar Normative Modelling of the Hippocampus Across the Human Lifespan.

bioRxiv : the preprint server for biology·2026
Same author

Linking effort-reward imbalance to work engagement: Job crafting as a mediator and overcommitment as a moderator among rural teachers.

Acta psychologica·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Guoyu Lan1, Laihong Zhang1, Tengfei Guo2

  • 1Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Plasma phosphorylated tau217 (p-tau217) assays show promise for Alzheimer's disease (AD) detection. Intermediate p-tau217 levels indicate higher dementia risk, necessitating further monitoring for early AD intervention.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Biomarker Discovery
  • Alzheimer's Disease Research

Background:

  • Phosphorylated tau217 (p-tau217) is a key biomarker for Alzheimer's disease (AD) neuropathology.
  • Evaluating commercial p-tau217 assays is crucial for detecting and monitoring AD progression.

Purpose of the Study:

  • To investigate the performance of four leading commercial plasma p-tau217 assays.
  • To assess the association between plasma p-tau217 levels and AD neuropathological changes, including Aβ plaques, tau tangles, and hippocampal atrophy.
  • To evaluate the predictive value of plasma p-tau217 for cognitive decline and dementia risk.

Main Methods:

  • Analysis of 363 non-dementia participants from the ADNI cohort using four distinct plasma p-tau217 assays.
  • Categorization of participants into negative, intermediate, and positive groups based on p-tau217 levels.
  • Longitudinal assessment of amyloid plaques (Aβ-PET), tau tangles (entorhinal tau-PET), hippocampal volume, and cognitive performance (PACC scores).

Main Results:

  • Plasma p-tau217 assays effectively identified AD neuropathology, with variations in intermediate zone percentages across assays.
  • Abnormal and intermediate plasma p-tau217 levels correlated with significant baseline abnormalities and longitudinal changes in Aβ-PET, tau-PET, hippocampal volume, and PACC scores.
  • Higher plasma p-tau217 levels, particularly in the positive and intermediate groups, were associated with increased risk of dementia over a mean follow-up of 6.8 years.

Conclusions:

  • Plasma p-tau217 assays are valuable tools for detecting and monitoring dynamic Alzheimer's disease progression.
  • Individuals with intermediate plasma p-tau217 levels require confirmatory testing and longitudinal monitoring due to elevated dementia risk.
  • This approach can identify a target population for early AD studies and interventions, potentially improving clinical trial screening for anti-amyloid therapies.